Filing Details

Accession Number:
0001209191-21-054797
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-03 16:54:08
Reporting Period:
2021-09-01
Accepted Time:
2021-09-03 16:54:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661460 Poseida Therapeutics Inc. PSTX Biological Products, (No Disgnostic Substances) (2836) 472846548
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1765987 Eric Ostertag C/O Poseida Therapeutics, Inc.
9390 Towne Centre Drive, Ste 200
San Diego CA 92121
Chief Executive Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-09-01 26,686 $8.46 3,711,789 No 4 S Indirect See footnote
Common Stock Disposition 2021-09-02 31,963 $8.34 3,679,826 No 4 S Indirect See footnote
Common Stock Disposition 2021-09-01 24,463 $8.46 3,406,384 No 4 S Indirect See footnote
Common Stock Disposition 2021-09-02 29,299 $8.34 3,377,085 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 654,134 Direct
Common Stock 629,194 Indirect See footnote
Common Stock 961,445 Indirect See footnote
Common Stock 200,696 Indirect See footnote
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.29 to $8.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.14 to $8.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
  6. The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
  7. The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
  8. The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.